Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stiefel Laboratories has entered into an arrangement with Allergan to develop, manufacture, distribute and promote dermatological products containing tazarotene.
Subscribe to our email newsletter
Under the terms of the transaction, Stiefel will utilize Allergan’s proprietary technology and tazarotene in several ways. Stiefel will co-promote Allergan’s Tazorac (tazarotene) to dermatologists in the US. Stiefel also will capitalize on its existing patent-protected technology and Allergan’s tazarotene compound to bring unique therapeutic options to market for a common dermatological disease.
Bill Humphries, chief commercial officer of Stiefel, said: “Tazorac will provide the perfect complement to our acne portfolio, which also includes Duac, and it will allow Stiefel to offer best-in-class topical acne treatments to our customers. Given our long-standing and well-established presence in the dermatology arena, we will be able make an immediate and important impact with Tazorac.”